TSS
RGLS

Two Sigma Securities’s Regulus Therapeutics RGLS Stock Holding History

Two Sigma Securities’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-38,451
Closed -$68.6K – 3501
2024
Q2 		$68.6K Buy
+38,451
New +$89.2K ﹤0.01% 2535
2021
Q3 		– Sell
-3,774
Closed -$31K – 1877
2021
Q2 		$31K Buy
+3,774
New +$42.1K ﹤0.01% 1430
2020
Q4 		– Sell
-1,666
Closed -$9K – 1898
2020
Q3 		$9K Buy
1,666
+475
+40% +$3.13K ﹤0.01% 1251
2020
Q2 		$8K Buy
+1,191
New +$7.79K ﹤0.01% 1320
2018
Q4 		– Sell
-146
Closed -$3K – 2716
2018
Q3 		$3K Buy
+146
New +$4.81K ﹤0.01% 2516
2018
Q2 		– Sell
-158
Closed -$14K – 2953
2018
Q1 		$14K Buy
+158
New +$21.1K ﹤0.01% 2595

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Securities's RGLS Position: Q3 2024 in Review

Two Sigma Securities sold out of Regulus Therapeutics (RGLS) in Q3 2024, closing a stake of 38,451 shares — an estimated $68.6K sold.

Two Sigma Securities first reported a position in RGLS in Q1 2018 and held it in 6 quarters. The position peaked at $68.6K in Q2 2024. 70 funds tracked by Wall St. Rank hold RGLS as of Q3 2024.

  • Two Sigma Securities reported no remaining Regulus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Two Sigma Securities sold 38,451 Regulus Therapeutics shares in Q3 2024, an estimated $68.6K.
  • Two Sigma Securities first reported a position in Regulus Therapeutics in Q1 2018 and held it in 6 quarters.
  • Two Sigma Securities's Regulus Therapeutics position peaked at $68.6K in Q2 2024.
  • 70 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2024.

Based on Two Sigma Securities's 13F filing for Q3 2024, filed 14 Nov 2024.